Sagimet Biosciences Files 2024 10-K
Ticker: SGMT · Form: 10-K · Filed: Mar 12, 2025 · CIK: 1400118
Sentiment: neutral
Topics: 10-K, annual-report, financials
TL;DR
Sagimet Biosciences filed its 2024 10-K, detailing financials for the year ending Dec 31, 2024.
AI Summary
Sagimet Biosciences Inc. filed its 2024 10-K on March 12, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly known as 3-V Biosciences, Inc., is based in San Mateo, California, and operates in the pharmaceutical preparations sector. Key financial data points such as retained earnings and additional paid-in capital for the fiscal years 2023 and 2024 are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Sagimet Biosciences' financial health and operational status for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — The filing is a standard annual report and does not inherently contain new risk-increasing information.
Key Numbers
- 30,674,855 — Total Assets (As of December 31, 2024)
- 21,375,402 — Total Liabilities (As of December 31, 2024)
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Filer of the 10-K
- 3-V Biosciences, Inc. (company) — Former company name
- 2024-12-31 (date) — Fiscal year end
- 20250312 (date) — Filing date
- San Mateo, CA (location) — Company headquarters
FAQ
What was Sagimet Biosciences Inc.'s net income or loss for the fiscal year ended December 31, 2024?
The provided text does not explicitly state the net income or loss for the fiscal year ended December 31, 2024. It focuses on balance sheet items like total assets and liabilities.
What are the details of Sagimet Biosciences Inc.'s revenue for the fiscal year ended December 31, 2024?
The provided text does not contain specific revenue figures for the fiscal year ended December 31, 2024.
What is the current status of Sagimet Biosciences Inc.'s research and development pipeline as detailed in the 2024 10-K?
The provided text is a header and summary of the 10-K filing and does not include details about the company's R&D pipeline.
Did Sagimet Biosciences Inc. undergo any significant acquisitions or divestitures in 2024?
The provided text does not mention any acquisitions or divestitures for Sagimet Biosciences Inc. in 2024.
What were the total operating expenses for Sagimet Biosciences Inc. in the fiscal year ended December 31, 2024?
The provided text does not specify the total operating expenses for Sagimet Biosciences Inc. for the fiscal year ended December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 12, 2025 regarding Sagimet Biosciences Inc. (SGMT).